# Compartmentalization of the Broad-Range Phospholipase C Activity to the Spreading Vacuole Is Critical for *Listeria monocytogenes* Virulence

P. S. Marie Yeung,† Yoojin Na, Amanda J. Kreuder,‡ and Hélène Marquis\*

*Department of Microbiology and Immunology, Cornell University, Ithaca, New York 14853-6401*

Received 23 June 2006/Returned for modification 21 August 2006/Accepted 12 October 2006

*Listeria monocytogenes* **is a bacterial pathogen that multiplies in the cytosol of host cells and spreads directly from cell to cell by using an actin-based mechanism of motility. The broad-range phospholipase C (PC-PLC) of** *L. monocytogenes* **contributes to bacterial escape from vacuoles formed upon cell-to-cell spread. PC-PLC is made as an inactive proenzyme whose activation requires cleavage of an N-terminal propeptide. During infection, PC-PLC is activated specifically in acidified vacuoles. To assess the importance of compartmentalizing PC-PLC activity during infection, we created a mutant that makes constitutively active PC-PLC (the** *plcB***pro mutant). Results from intracellular growth and cell-to-cell spread assays showed that the** *plcB***pro mutant was sensitive to gentamicin, suggesting that unregulated PC-PLC activity causes damage to host cell membranes. This was confirmed by the observation of a twofold increase in staining of live infected cells by a non-membrane-permeant DNA fluorescent dye. However, membrane damage was not sufficient to cause cell lysis and was dependent on bacterial cell-to-cell spread, suggesting that damage was localized to bacteriumcontaining filopodia. Using an in vivo competitive infection assay, we observed that the** *plcB***pro mutant was outcompeted up to 200-fold by the wild-type strain in BALB/c mice. Virulence attenuation was greater when mice were infected orally than when they were infected intravenously, presumably because the** *plcB***pro mutant was initially outcompeted in the intestines, reducing the number of mutant bacteria reaching the liver and spleen. Together, these results emphasize the importance for** *L. monocytogenes* **virulence of compartmentalizing the activity of PC-PLC during infection.**

*Listeria monocytogenes* is an opportunistic bacterial pathogen that has the ability to remain sequestered within host cells during its entire life cycle (15, 26). Upon entry into host cells, bacteria escape from membrane-bound vacuoles and begin multiplying in the cytosol of their host. During intracellular growth, bacteria use an actin-based mechanism of motility to induce the formation of membrane filopodia, which are taken up by neighboring cells, enabling bacteria to spread directly from cell to cell. The virulence of *L. monocytogenes* is directly related to its efficacy at (i) escaping primary and secondary vacuoles, formed upon initial entry into a host cell and upon cell-to-cell spread, respectively, and (ii) remaining sequestered within host cells (4, 7, 8, 11, 23, 26).

Bacterial factors implicated in vacuolar lysis include a poreforming hemolysin called listeriolysin O (LLO), a phosphatidylinositol-specific phospholipase C (PI-PLC), and a broadrange phospholipase C (PC-PLC). LLO is essential for bacterial escape from vacuoles of most cell lines (18), whereas the phospholipases are dispensable but enhance the efficacy of vacuolar escape (4, 23, 27). In the absence of PI-PLC, bacteria have a significant decrease in escape from primary vacuoles

and a small defect in the ability to spread from cell to cell (4). The absence of PC-PLC does not affect escape from primary vacuoles but significantly reduces the bacterium's ability to escape secondary vacuoles (23, 27). The two bacterial phospholipases appear to have overlapping functions, as a double phospholipase mutant is more deficient in escape from secondary vacuoles than the sum of the defects observed with individual mutants (23). Exceptionally, LLO is dispensable for escape from vacuoles in cultured human cells, in which PC-PLC can substitute for LLO in mediating vacuolar escape (10, 12, 16, 18). In vivo, LLO-negative bacteria completely fail to grow in livers and spleens of infected mice (6), which is consistent with their inability to escape from primary vacuoles. On the other hand, PI-PLC and PC-PLC are not essential for growth of *L. monocytogenes* in vivo, although individual PI-PLC and PC-PLC deletion mutants are recovered in much lower numbers from livers and spleens of infected mice, supporting their role in virulence (4, 20).

Remarkably, the activities of these three membrane-targeting factors appear to be restricted to vacuolar membranes, as infected host cells show few signs of toxicity and intracellular bacteria are protected from gentamicin, an antibiotic that does not diffuse across membranes (4, 18, 23). In fact, LLO's poreforming ability is optimal at pH 5.9, a pH value that would be reached only in vacuoles, and the protein has an intracellular half-life of <15 min (2, 22). Accordingly, mutations that affect compartmentalization of LLO activity are cytotoxic and compromise the ability of *L. monocytogenes* to remain sequestered within host cells, resulting in severe virulence attenuation (7, 8). The activity of PC-PLC is also tightly regulated during

<sup>\*</sup> Corresponding author. Mailing address: Department of Microbiology and Immunology, Cornell University, VMC C5-169, Ithaca, NY 14853-6401. Phone: (607) 253-3273. Fax: (607) 253-3383. E-mail: hm72 @cornell.edu.

<sup>†</sup> Present address: Biological Sciences Department, California Polytechnic State University, San Luis Obispo, CA 93407-0401.

<sup>‡</sup> Present address: Iowa State University, College of Veterinary

Published ahead of print on 23 October 2006.

intracellular infection. PC-PLC is made as an inactive proenzyme whose activation requires proteolytic cleavage of a 24 residue propeptide (17, 19, 27). PC-PLC activation is assisted by a metalloprotease (Mpl) and is dependent on cell-to-cell spread and vacuolar acidification, indicating that it occurs specifically in vacuoles (13, 19). Bacteria multiplying in the cytosol of host cells secrete the inactive form of PC-PLC but also maintain a pool of inactive PC-PLC at the membrane-cell wall interface (14, 24). Similar to the case for LLO, PC-PLC secreted into the cytosol of infected cells is degraded by the proteasome, with a half-life of  $\leq$ 15 min (13). In vacuoles, the pool of bacterium-associated PC-PLC is activated and translocated across the bacterial cell wall within minutes of a decrease in pH (14).

In this study, we investigated the biological relevance of compartmentalizing PC-PLC activity during intracellular infection. A mutant of *L. monocytogenes* making a constitutively active form of PC-PLC (the *plcB* $\Delta$ pro mutant) was used. Previously, we showed that secretion and activation of this mutant form of PC-PLC are no longer regulated by pH and by Mpl (28). Here we report that the  $plcB\Delta$ pro mutant is not cytotoxic, although it compromises host cell membrane integrity during cell-to-cell spread. Remarkably, the *plcB* $\Delta$ pro mutant shows strong attenuation in mice, indicating that similar to the case for LLO, correct compartmentalization of PC-PLC activity is imperative for the virulence of *L. monocytogenes*.

#### **MATERIALS AND METHODS**

**Bacterial strains and cell cultures.** The *L. monocytogenes* 10403S wild-type strain (3) and the isogenic mutant HEL-335 were used in this study. HEL-335, which is identified as the  $plcB\Delta$ pro mutant, contains a deletion of the sequence coding for the PC-PLC propeptide, generating a constitutively active form of PC-PLC (28). In addition, strain DP-L3903, a fully virulent derivative of strain 10403S carrying Tn*917* in its chromosome, was used for in vivo assays (1). DP-L3903 is erythromycin resistant and is identified as the Em<sup>r</sup> wild type in this paper. For tissue culture assays, the wild-type strain and the *plcB*Apro mutant were grown statically overnight at 30°C in brain heart infusion medium. For in vivo assays, the Em<sup>r</sup> wild type and the  $plcB\Delta$ pro mutant were grown at 30°C (for oral infections) or 37°C (for intravenous [i.v.] infections) at 250 rpm in brain heart infusion broth supplemented with  $200 \mu g/ml$  streptomycin to an optical density at 600 mm of 0.4 to 0.5. A regression formula was developed empirically to determine the number of CFU per ml. The mouse macrophage-like J774 cell line and mouse fibroblast L2 cell line were propagated in Dulbecco's modified Eagle's medium supplemented with 7.5% fetal bovine serum and 2 mM glutamine. Cell cultures were incubated at  $37^{\circ}$ C with  $5\%$  CO<sub>2</sub>.

**Plaque assay.** A plaque assay was used as an indication of bacterial cell-to-cell spreading efficacy. The method described by Sun et al. (25) was adopted. L2 cells  $(7 \times 10^5)$  were seeded in each well of a six-well plate 2 days prior to infection with  $2 \times 10^5$  to  $4 \times 10^5$  bacterial cells. At 60 min postinfection, cells were washed three times with phosphate-buffered saline (PBS) and overlaid with a semisolid medium containing defined concentrations of gentamicin. At 4 days postinfection, plaques were stained with neutral red. The mean plaque surface area formed by the mutant was compared with that of the wild type. The relative plaque size is reported as a percentage of the wild-type plaque size.

**Membrane permeability assay.** To assess host cell membrane integrity, livecell staining was performed on infected J774 cells with a fluorescent non-membrane-permeant SYTOX orange nucleic acid stain (Invitrogen). J774 cells (6  $\times$ 105 ) were seeded in glass-bottomed 35-mm dishes (MatTek Corporation) 1 day prior to infection with  $5 \times 10^6$  to  $10 \times 10^6$  bacterial cells. Cells were infected 20 to 60 min apart with the wild-type and  $plcB\Delta$ pro mutant strains. Infected cells were washed at 30 min postinfection, and gentamicin (50  $\mu$ g/ml) was added at 1 h postinfection for a period of 2 h. At 6 h postinfection, infected cells were washed with PBS, stained for 20 min at room temperature with SYTOX diluted in TBS (25 mM Tris, pH 8.0, 150 mM NaCl, 1% bovine serum albumin), washed with TBS, and replenished with 1 ml of clear Dulbecco's modified Eagle's medium. Images were captured with a  $\times 40$  lens, using a confocal microscope with a

krypton laser and transmitted light. For each experiment, images from 8 to 10 fields were captured, and  $1 \times 10^3$  to  $2 \times 10^3$  infected host cells were counted per sample. The fields were chosen at random. The experiment was repeated five times, and for each experiment the ratio of stained cells relative to the total number of cells was determined for cells infected with the wild type or the  $plcB\Delta$ pro mutant. Diff Quick staining was also performed on another set of coverslips to verify that every host cell was infected.

**Intracellular growth kinetics.** To evaluate the bacterial ability to multiply inside host cells, J774 cells were infected, followed by enumeration of intracellular bacterial cells (18). J774 ( $1.5 \times 10^6$ ) cells were seeded in 60-mm petri dishes containing 14 12-mm alcohol-flamed round coverslips 1 day prior to infection. *L. monocytogenes* cells from overnight cultures were washed once with PBS, and  $5 \times 10^5$  to  $10 \times 10^5$  bacteria were used to infect host cells. At 30 min postinfection, cells were washed three times with PBS and replenished with fresh medium. Gentamicin was added at 1 h postinfection at a final concentration of  $50 \mu g/ml$  to kill extracellular bacteria. To determine if gentamicin influences the growth kinetics of intracellular bacteria, cells were washed once more with PBS at 3 h postinfection and replenished with fresh medium, with or without gentamicin, as indicated in the figure legends. At defined time points (2, 5, 8, and 11 h postinfection), host cells on three coverslips were lysed by vortexing each coverslip in sterile  $H_2O$  for 20 s. Appropriate dilutions were then plated on Luria-Bertani (LB) medium to determine the number of CFU per coverslip. To determine the intracellular growth of bacteria devoid of cell-to-cell movement, cytochalasin D, an inhibitor of actin polymerization, was added at a final concentration of 0.5  $\mu$ g/ml at 3 h postinfection. Experiments were repeated a minimum of three times. The doubling time between 5 h and 8 h postinfection was calculated based on the following formula:  $\ln 2/[\ln (N_t/N_0)/(t_n - t_0)]$ , where  $N_t$  is the number of bacteria present at a given time  $t$  (in min),  $N_0$  is the number of bacteria present initially, and  $t_n - t_0$  is the corresponding time interval between  $N_1$  and  $N_0$ .

**In vivo proliferation.** Six- to 8-week-old female BALB/c mice (Taconic, Hudson, NY) were infected with log-phase bacterial cells orally or i.v., using a competitive index (CI) approach (1). For oral infection, mice were fasted for 2 h prior to and after infection. Bacteria were washed once in PBS and suspended in an appropriate volume of PBS. The  $Em<sup>r</sup>$  wild type and the  $plcB\Delta p$ ro mutant were mixed at equal concentrations, and each mouse received a  $250$ - $\mu$ l dose containing approximately  $4 \times 10^9$  CFU with a gavage needle. For i.v. infection, 200- $\mu$ l inocula containing approximately  $2 \times 10^4$  bacteria in an equal mixture of the Em<sup>r</sup> wild type and the  $plcB\Delta$ pro mutant were injected into tail veins. At defined time points, livers, spleens, and mesenteric lymph nodes (MLN) were harvested from sacrificed mice and homogenized in 5 ml of buffer containing  $0.5\%$  NP-40 and  $200 \mu g/ml$  streptomycin. Intestines were cut longitudinally, rid of fecal materials, rinsed in three changes of PBS (10 ml each), and homogenized in 5 ml of buffer containing 0.5% NP-40, 0.2 mM EDTA, and 200 µg/ml streptomycin. Suspensions were plated on LB agar supplemented with streptomycin to recover *L. monocytogenes* cells. Up to 200 colonies were streaked onto LB agar supplemented with 200  $\mu$ g/ml streptomycin and 1  $\mu$ g/ml erythromycin or onto activated charcoal (0.2%)-treated LB supplemented with 25 mM glucose-1-phosphate and 1.25% egg yolk (LB-G1P-EY). While the Em<sup>r</sup> wild-type strain was resistant to erythromycin, the  $plcB\Delta$ pro mutant was unable to grow in medium containing erythromycin. The *plcB* $\Delta$ pro mutant also exhibited an elevated level of PC-PLC activity after 24 h of incubation at 37°C on LB-G1P-EY plates (28). The CI was calculated by the formula  $\text{CI}_{\text{out}}/\text{CI}_{\text{in}}$ , where  $\text{CI}_{\text{out}}$  is the ratio of the  $plcB\Delta\text{pro}$ mutant to the  $Em<sup>r</sup>$  wild type postinfection and  $CI<sub>in</sub>$  is the ratio of the  $plcB\Delta pro$ mutant to the Em<sup>r</sup> wild type in the inoculum (i.e., preinfection). A CI of 1 indicates that the  $Em<sup>r</sup>$  wild type and the  $plcB\Delta pro$  mutant proliferated equally in the organ. In some events where no  $plcB\Delta$ pro mutant was recovered from  $>100$ (but  $\leq$ 200) colonies, we estimated the CI<sub>out</sub> by assuming that the next colony would have been from the mutant strain.

**Statistical analyses.** Experimental data were analyzed statistically to evaluate the significance of differences between the wild-type and mutant strains. For each experiment from the plaque assay, the surface area of plaques formed by the  $plcB\Delta$ pro mutant was normalized relative to that of plaques formed by the wild type. A one-sample *t* test was conducted to test if the mutant plaque size was significantly different from 100%, which was defined as the wild-type plaque size. Likewise, for each experiment from the membrane permeability assay, the ratio obtained with *plcB* $\Delta$ pro mutant-infected cells was normalized to that obtained with wild type-infected cells. The normalized value was tested, by a one-sample *t* test, with the null hypothesis of the mean value equaling 1. Data obtained from the intracellular growth kinetics assays were analyzed using a two-sample *t* test to determine the effect of cytochalasin D on the doubling time. The mouse CI assay was analyzed with a one-sample *t* test using log-transformed CI to determine if the CI were significantly less than 1.



FIG. 1. Cell-to-cell spreading efficacy of *L. monocytogenes* wildtype strain (top row) and *plcB*Apro mutant (bottom row) in infected mouse fibroblast L2 cells in the presence of gentamicin. Infected cells were washed at 60 min postinfection and overlaid with a semisolid medium containing 2, 5, or 10  $\mu$ g/ml gentamicin. At 4 days postinfection, the monolayer was stained with neutral red, a weak cationic dye that diffuses across intact membranes and cumulates intracellularly. Plaques are defined by the absence of staining, which is indicative of major cell damage or cell lysis.

# **RESULTS**

**Unregulated secretion of active PC-PLC by** *L. monocytogenes* **compromises host cell membrane integrity during intracellular infection.** During intracellular infection, Mpl-mediated PC-PLC activation occurs specifically in vacuoles and requires a decrease in vacuolar pH  $(13)$ . However, the *plcB* $\Delta$ pro mutant secretes active PC-PLC independently of Mpl and pH (28). Constitutive secretion of active PC-PLC is not cytotoxic to the producer bacteria. We hypothesized that the inability of *L. monocytogenes* to compartmentalize PC-PLC activity during intracellular infection would affect host cell membrane integrity. To test this hypothesis, we analyzed bacterial sensitivity to gentamicin during intracellular infection. Gentamicin was added to the extracellular milieu to specifically kill extracellular bacteria, as it cannot diffuse across intact membranes. However, gentamicin may access the intracellular milieu if host membrane integrity is compromised. Mouse fibroblast L2 cells were infected and then overlaid with medium-containing soft agar supplemented with three different concentrations of gentamicin. Four days after infection, the plaques were visualized by staining the monolayer with neutral red, a weak cationic dye that diffuses across intact membranes and cumulates intracellularly. Plaques are defined by the absence of staining, which is an indication of major cell damage, presumably as a result of overwhelming infection, and the size of plaques reflects the ability of bacteria to spread from cell to cell. If host membrane integrity was compromised early after infection, then bacterial intracellular growth and cell-to-cell spread would be reduced. Plaques formed by the  $plcB\Delta$ pro mutant were compared to those formed by the wild-type strain for the same gentamicin concentration. The surface areas of plaques formed by the  $plcB\Delta$ pro mutant were 93% (*P* = 0.05), 84% (*P* = 0.02), and 81% ( $P = 0.01$ ) relative to that of wild-type plaques with 2, 5, and 10  $\mu$ g/ml of gentamicin, respectively (Fig. 1). However, the most striking difference was the appearance of the plaques. Plaques formed by the wild-type strain were uniformly clear at all gentamicin concentrations. Similarly, plaques formed by the



FIG. 2. Micrographs of J774 cells infected with the wild-type strain or the  $\nu$ lc*B* $\Delta$ pro mutant. Infected host cells were washed at 30 min postinfection. Gentamicin (50  $\mu$ g/ml) was added to the medium at 1 h postinfection and maintained until the end of the experiment (top row) or removed at 3 h postinfection (bottom row). Cells on coverslips were stained with Diff Quick at 8 h postinfection. Images were taken with  $a \times 60$  lens.

 $plcB\Delta$ pro mutant were uniformly clear at 2  $\mu$ g/ml of gentamicin. At 5  $\mu$ g/ml of gentamicin, plaques formed by the  $plcB\Delta pro$ mutant had a clear center surrounded by a zone of partial staining delimited by a thin clear zone. At 10  $\mu$ g/ml of gentamicin, plaques formed by the  $plcB\Delta$ pro mutant showed a small clear central zone surrounded by a large zone of different staining intensity. The unusual appearance of plaques formed by the  $plcB\Delta$ pro mutant at 5 and 10  $\mu$ g/ml of gentamicin suggested that the antibiotic had a protective effect on host cells, presumably by impairing the growth of intracellular bacteria.

The plaque assay results indicated that unregulated secretion of active PC-PLC affects host membrane integrity, as the size and appearance of plaques formed by the  $plcB\Delta$ pro mutant differed from those of wild-type plaques in a gentamicindependent manner. To evaluate the extent of damage caused by infection, we quantified the levels of lactate dehydrogenase (LDH) released into the supernatants of infected murine macrophage-like J774 cells, using the Cytotox 96 nonradioactive cytotoxicity assay (Promega) according to the manufacturer's instructions. LDH is normally contained within the cytosol of eukaryotic cells but is released into the extracellular milieu upon cell lysis. Surprisingly, no differences were observed in LDH release from samples infected with the wild type or the  $plcB\Delta$ pro mutant strain, even when gentamicin was not used to allow intracellular bacterial growth in permeabilized host cells (data not shown). In agreement with this result, the appearances of J774 cells infected with either bacterial strain were indistinguishable, as determined by microscopic examination of fixed and stained cells (Fig. 2). The nuclei and cytosol of infected cells appeared to be normal, and bacterium-containing filopodia were observed whether or not gentamicin was



FIG. 3. Staining of live infected J774 cells with a fluorescent, nonmembrane-permeant nucleic acid dye. Host cells were infected with the wild type or the  $plcB\Delta$ pro mutant for 6 h, with the addition of 50 g/ml gentamicin between 1 h and 3 h postinfection. Live infected cells were stained at 6 h postinfection. Images were captured with a  $\times 40$ lens, using a confocal microscope with a krypton laser and transmitted light. Host cells with compromised membranes are stained red. The images show overlays of phase-contrast and fluorescence images of host cells infected with the wild-type strain  $(A)$  or the  $plcB\Delta$ pro mutant (B). (C) Ratios of stained cells to the total number of infected host cells ( $1 \times 10^3$  to  $2 \times 10^3$  per sample; *n* = 5 per sample). The wild type was set to have a ratio of 1. Statistical analysis of the data indicated that the *P* value was 0.018.

present. These observations indicated that unregulated secretion of active PC-PLC during intracellular infection did not cause host cell lysis.

To evaluate host membrane integrity in a more sensitive manner, we stained live infected cells with a fluorescent, nonmembrane-permeant nucleic acid stain. In this assay, infected J774 cells were maintained in a gentamicin-free medium from 3 h to 6 h postinfection to prevent inhibition of intracellular bacterial growth in damaged cells. The nucleic acid dye was added to live cells, and the ratio of stained to unstained cells was determined by microscopy. In this assay, twofold more stained cells were observed in samples infected with the  $plcB\Delta$ pro mutant than in samples infected with the wild-type strain  $(P = 0.018)$  (Fig. 3). Taken together, the results indicate that unregulated secretion of active PC-PLC by *L. monocytogenes* during intracellular infection compromises host cell membrane integrity without causing host cell lysis.

**Host cell membrane damage occurs during cell-to-cell spread.** During intracellular infection, *L. monocytogenes* moves randomly in the host cytosol, bouncing on membranes and organelles (21). Sporadically, moving bacteria induce the formation of membrane filopodia, at which point bacteria become closely surrounded by host cell membranes. Based on the premise that constitutive secretion of active PC-PLC compromises host membrane integrity in the absence of major cell damage or cell lysis, we hypothesized that it acts specifically on filopodial membranes. To this end, we first determined the intracellular growth kinetics of bacteria. In the absence of gentamicin, the growth rate of the  $plcB\Delta$ pro mutant was the



FIG. 4. Growth kinetics of wild-type (squares) and  $plcB\Delta$ pro mutant (inverted triangles) strains in J774 cells. Infected host cells were washed at 30 min postinfection, and gentamicin (50  $\mu$ g/ml) was added at 1 h postinfection. At 3 h postinfection, the samples were washed, and cells were replenished with fresh medium alone (open symbols, dotted lines) or fresh medium containing gentamicin (closed symbols, solid lines). At 2, 5, 8, and 11 h postinfection, host cells on coverslips were lysed to release bacteria, which were subsequently enumerated by standard plate counts. Means  $\pm$  standard deviations for one representative experiment are shown. The experiment was repeated at least three times.

same as that of the wild-type strain at all time points (Fig. 4). However, the intracellular growth kinetics was influenced by the presence of extracellular gentamicin. While the growth rate of the  $plcB\Delta$ pro mutant was initially the same as that of the wild-type strain (between 2 and 5 h postinfection), it was lower than that of the wild-type strain after 5 h (Fig. 4 and Table 1). This change in kinetics is supported by our hypothesis that gentamicin acts on intracellular bacteria as they begin to spread from cell to cell. To test whether or not the damage was restricted to filopodial membranes, actin-based motility was restricted with cytochalasin D, and thus cell-to-cell movement was prohibited. Inhibition of cell-to-cell spread did not affect the intracellular kinetics of the wild-type strain or the *plcB* $\Delta$ pro mutant between 2 and 5 h postinfection (data not shown). It also did not affect the intracellular kinetics of the wild-type

TABLE 1. Intracellular growth rates of *L. monocytogenes* in J774 cells between 5 and 8 h postinfection*<sup>a</sup>*

Strain	Presence of cytochalasin $D^b$	Mean doubling time $(min)^c \pm SD$	n	P <sup>d</sup>
Wild type	-	$81.3 \pm 17.8$	8	0.538
	$+$	$90.3 \pm 34.1$		
$plcB\Delta pro$ mutant	-	$118.4 \pm 33.7$		0.032
		$74.3 \pm 5.6$		

<sup>*a*</sup> Gentamicin (50  $\mu$ g/ml) was present in the extracellular medium from 1 h postinfection until the end of the experiment.

 $\phi$  Cytochalasin D (0.5  $\mu$ g/ml) was added to infected cells at 3 h postinfection. *c* Doubling times were calculated as indicated in Materials and Methods.

*<sup>d</sup>* A two-sample *t* test was conducted to compare the intracellular growth rates with and without cytochalasin D for the wild-type strain (top value). The same test was conducted for the *plcB* $\Delta$ pro mutant strain (bottom value).

strain between 5 and 8 h postinfection (Table 1). However, the growth rate of the mutant was nearly twofold higher between 5 and 8 h postinfection in the presence of cytochalasin D. The difference in growth rates between wild type- and  $plcB\Delta pro$ mutant-infected cells treated with cytochalasin D was not statistically significant ( $P = 0.36$ ). These results indicate that the ability of the  $plcB\Delta$ pro mutant to damage host cell membranes is dependent on cell-to-cell spread.

**Unregulated secretion of active PC-PLC compromises the virulence of** *L. monocytogenes***.** Given that constitutive secretion of active PC-PLC induces host cell damage in tissue culture models, our next step was to evaluate the importance of compartmentalizing PC-PLC activity for the virulence of *L. monocytogenes* in an animal model. BALB/c mice were infected orally or intravenously with an equal mixture of two strains, i.e., a fully virulent erythromycin-resistant derivative of the wild-type strain (the  $Em<sup>r</sup>$  wild type) and the  $plcB\Delta$ pro mutant. The virulence of the  $plcB\Delta$ pro mutant was evaluated by calculating the ratio of the two strains recovered from various organs at specific times after infection. The results are reported as CI, which were calculated as described in Materials and Methods. A fully virulent strain would be expected to have a CI of  $\geq$ 1, whereas an attenuated strain would have a CI below 1. For mice infected orally, CI were determined on days 2, 3, and 4 postinfection for intestines, MLN, livers, and spleens. CI were not evaluated on day 1 for orally infected mice because the numbers of bacteria per organ were often below detectable levels or too low. For mice infected intravenously, bacteria were recovered from livers and spleens as early as 7 h postinfection, and CI were calculated at 7 h and on days 1, 2, and 3.

In the intestines of orally infected mice, the  $plcB\Delta$ pro mutant was outcompeted  $\approx$  15- to 25-fold by the Em<sup>r</sup> wild type on days 2 and 3 postinfection and  $\approx$  100-fold by day 4 postinfection (Fig. 5). In livers of orally infected mice, the  $plcB\Delta pro$ mutant was outcompeted  $\approx$  50-fold by the Em<sup>r</sup> wild type on day 2 postinfection and 100-fold on days 3 and 4 postinfection. In spleens of orally infected mice, the  $plcB\Delta$ pro mutant was outcompeted  $\approx$  20-fold by the Em<sup>r</sup> wild type on day 2 postinfection and 200-fold on days 3 and 4 postinfection. In MLN, the  $plcB\Delta$ pro mutant was outcompeted by the  $Em<sup>r</sup>$  wild type to a lesser degree, and CI showed a large degree of variability between mice on days 2 and 4 postinfection. Statistical analysis of these results indicated that the  $plcB\Delta$ pro mutant was significantly outcompeted by the Em<sup>r</sup> wild type in intestines, livers, and spleens of infected mice at all times but not in MLN on days 2 and 4 postinfection. It is important that in some circumstances the mutant was not recovered and the median CI was calculated based on some estimated values (see Materials and Methods). The estimated CI, which are cross-marked on the figure, are potentially higher than the actual CI. Hence, the mutant is potentially attenuated to a greater extent than estimated.

For mice infected intravenously, CI from livers and spleens were not significantly different from 1 at 7 h postinfection, indicating that the mutant was not defective in the first stage of infection. As with oral infection, CI dropped below 1 in the subsequent stages of infection, but to a lesser extent. In livers of mice infected intravenously, the  $plcB\Delta$ pro mutant was outcompeted nearly 10-fold by the Em<sup>r</sup> wild type on days 1 and 2 postinfection and  $\approx$ 100-fold by day 3 postinfection. In

spleens, it took 2 days for the  $Em<sup>r</sup>$  wild type to outcompete the  $plcB\Delta$ pro mutant. The  $Em<sup>r</sup>$  wild type outcompeted the  $plcB\Delta$ pro mutant 4- and 35-fold by days 2 and 3 postinfection, respectively.

The median of total CFU recovered from tissues was determined and compared to the median CI to evaluate the correlation between the two sets of data (Fig. 6). In most instances, the median CI within a tissue decreased, while the median CFU increased or remained constant, indicating that wild-type bacteria were proliferating as the mutant was being eliminated. Together, the results from in vivo infections indicate that the  $plcB\Delta$ pro mutant is significantly attenuated in the mouse.

# **DISCUSSION**

*L. monocytogenes* has the remarkable ability to regulate the activities of two membrane-damaging virulence factors, namely, LLO and PC-PLC. During intracellular infection, bacteria are temporarily located in membrane-bound vacuoles, where LLO and PC-PLC operate (2, 13). Regulation of LLO and PC-PLC activities is controlled in part by pH, as inhibition of vacuolar acidification prohibits these factors from acting. *L. monocytogenes* mutants that have lost the ability to compartmentalize LLO activity are cytotoxic and strongly attenuated (7, 8). In this study, we show that an *L. monocytogenes* mutant that constitutively secretes active PC-PLC is not cytotoxic. However, this mutant compromises host cell membrane integrity in a manner that is dependent on cell-to-cell spread, suggesting that membrane damage is limited to filopodia formed by moving bacteria. Moreover, the lack of compartmentalization of PC-PLC activity during infection significantly decreases the virulence of *L. monocytogenes*.

PC-PLC is made as a proenzyme whose activation requires a decrease in pH (13). During intracellular infection, *L. monocytogenes* maintains a pool of PC-PLC in its proform at the membrane–cell-wall interface (24). Upon vacuolar acidification, the pool of bacterium-associated PC-PLC is rapidly activated and translocated across the cell wall in an Mpl-dependent manner (14, 28). To study the biological relevance of regulating PC-PLC activity during intracellular infection, we made a PC-PLC mutant whose activation and secretion are no longer regulated by pH and Mpl (28). The behavior of this mutant, the  $plcB\Delta$ pro mutant, was indistinguishable from that of the isogenic wild-type strain with regard to growth kinetics in broth and sensitivity to acid stress and bile salts (data not shown). The only remarkable phenotypic difference was the size of the zone of opacity generated on LB-G1P-EY plates, indicating increased levels of PC-PLC activity (28). The  $plcB\Delta$ pro mutant was used in this study to evaluate the importance of *L. monocytogenes* regulation of PC-PLC activity during infection.

Cells infected with the  $plcB\Delta pro$  mutant did not show signs of cytotoxicity. However, we have previously shown that pHinduced release and activation of bacterium-associated PC-PLC from intracellular bacteria are cytotoxic (14). In the previous study, the intracellular pH of infected cells was equilibrated to the desired pH by using a potassium-based buffer and a potassium ionophore, resulting in a synchronized and rapid release of active PC-PLC from every intracellular bacterium. This massive release of active PC-PLC in the cy-



BALB/c mice were initially infected with equal concentrations of the Em<sup>r</sup> wild type and the *plcB*Apro mutant. At defined time points (2 to 4 days for oral infection; 7 h and 1 to 3 days for i.v. infection), mice were sacrificed, and bacteria residing in various organs were enumerated. Livers and spleens were harvested from mice infected intravenously. In addition to these two organs, whole intestines and MLN were harvested from mice infected orally. Each dot represents the CI for an individual mouse. Crossed dots represent estimated CI when the mutant was not recovered from the corresponding mice. The horizontal lines represent the median CI for each treatment group. A CI of <1 indicates that the *plcB*Δpro mutant's virulence was attenuated. Data were analyzed with a one-sample *t* test.  $*, P < 0.05; **, P < 0.001; ***, P < 0.0001$ .

tosol of infected cells is cytotoxic. In contrast to that phenomenon, the  $plcB\Delta$ pro mutant does not cumulate a pool of PC-PLC, as the active form of PC-PLC appears to diffuse unrestrictively across the bacterial cell wall (28). In addition,

the turnover rate of active PC-PLC in the cytosol of cells infected with the  $plcB\Delta$ pro mutant could be high, preventing accumulation of this enzyme to a concentration that is detrimental to host cells. Therefore, constant release and, perhaps,



bar graph, in parallel with the median CFU harvested from tissues of the same group of mice. Median CI are shown with black bars and the left *y* axis scale, and median CFU are shown with white bars and the right *y* axis scale. The left panel represents data for mice infected orally, and the right panel represents data for mice infected i.v.

rapid turnover of active PC-PLC in the cytosol of infected cells prevented the enzyme from causing irreversible membrane damage.

The  $plcB\Delta$ pro mutant became sensitive to gentamicin during intracellular infection. This sensitivity to gentamicin was abolished by preventing bacteria from forming filopodia, indicating that it was not due to an intrinsic increased bacterial sensitivity to gentamicin but rather to leakage of the antibiotic within infected cells as a result of filopodium formation. Concomitantly, using a non-membrane-permeant nucleic acid stain, cells were shown to be twice as sensitive to permeabilization when infected with the  $plcB\Delta$ pro mutant as they were when infected with the wild-type strain. It is conceivable that membrane damage is more likely to occur during cell-to-cell spread when bacteria are tightly apposed to host cell membranes in filopodia. Release of active PC-PLC by *plcB* $\Delta$ pro mutant bacteria in filopodia would result in localized and steady hydrolysis of membrane phospholipids, compromising membrane integrity and its ability to prevent diffusion of gentamicin. Consequently, intracellular growth of bacteria would begin to stall when moving bacteria initiate filopodium formation, which may explain the plaquing phenotype. Plaques formed by the wild-type strain in the presence of gentamicin at  $10 \mu g/ml$  were relatively clear, whereas those formed by the  $plcB\Delta$ pro mutant were darker after staining of the monolayers with neutral red. Since neutral red diffuses across membranes and cumulates within live cells, the plaquing phenotype indicates that cells infected with the  $plcB\Delta$ pro mutant were not as damaged as cells infected with the wild-type strain, presumably as a result of a lower intracellular bacterial density.

The  $plcB\Delta$ pro mutant was outcompeted up to 200-fold by the Emr wild type in a mouse competitive infection model. It is not clear why the  $plcB\Delta$ pro mutant was attenuated in vivo. In tissue culture cells, the mutant strain behaved similarly to the wild-type strain with regard to invasion and escape from vacuoles (data not shown). Moreover, the *plcB* $\Delta$ pro mutant did not show an intracellular growth defect or a cell-to-cell spreading defect in the absence of gentamicin. The only observed difference between the wild-type strain and the mutant was a twofold increase in host membrane permeability during intracellular growth. Conceivably, this increase in host membrane permeability carries greater consequences in vivo, as damaged cells may hasten and amplify the inflammatory response to infection. An amplified inflammatory response would have affected the wild-type strain as well as the mutant strain in a competitive assay. Absolute bacterial numbers recovered from internal organs did not decrease overtime, but CI did, indicating that Em<sup>r</sup> wild-type bacteria were proliferating. However, it remains a possibility that the rate of proliferation of the Emr wild type would have been greater in the absence of the  $plcB\Delta$ pro mutant.

The kinetics of *L. monocytogenes* in the initial phase of an intravenous infection in mice has been established (9). Within 10 min of infection, 60% and 5% of bacteria are found in the liver and the spleen, respectively, but 90% of the bacteria reaching the liver are killed by neutrophils within the first 6 h of infection  $(5, 9)$ . It appears that the *plcB* $\Delta$ pro mutant was not more susceptible than the  $Em<sup>r</sup>$  wild type to killing by neutrophils, as indicated by the CI obtained at 7 h postinfection. In addition, the  $plcB\Delta$ pro mutant was not more susceptible than the wild-type strain to killing by activated mouse bone marrowderived macrophages (data not shown). However, these observations do not eliminate the possibility that damaged host cells are better targets for inflammatory cells and, consequently, that cells infected with the *plcB* $\Delta$ pro mutant may be eliminated more readily than those infected with the  $Em<sup>r</sup>$  wild type at a time during infection when bacteria begin to spread from cell to cell.

Mesenteric lymph nodes from infected mice did not show the same CI pattern as that for other tissues. The data points were much more scattered on days 2 and 4 post-oral infection, and the day 4 median CI was 6- to 12-fold higher for MLN than for intestines, livers, and spleens. Perhaps MLN are not the main source of infection of the liver and spleen after oral infection with *L. monocytogenes*.

The  $plcB\Delta$ pro mutant was more attenuated in mice infected orally than in those infected intravenously. This difference is unlikely due to a decreased ability of the  $plcB\Delta$ pro mutant to invade cells of the intestinal tract, as it was not defective in invasion of different cell lines, such as Caco-2 human intestinal

epithelial cells, L2 mouse fibroblasts, and J774 mouse macrophage-like cells (data not shown). In addition, the mutant was not more sensitive than the wild-type strain to acid stress and bile salts (data not shown). Conceivably, this difference only reflects the inability of the mutant to perform as well as the wild-type strain in any infected tissue. Invasion of the liver and spleen following an oral infection takes 1 to 2 days according to the absolute bacterial numbers obtained in the present study. In comparison, invasion of the liver and spleen was observed at 7 h postinfection and has been reported to occur as early as 10 min postinfection following an intravenous infection (9). The difference in attenuation between orally and intravenously infected mice may simply reflect a cumulative effect of the  $plcB\Delta$ pro mutant being outcompeted by the  $Em<sup>r</sup>$  wild type in the intestines before translocation to the liver and spleen.

In summary, this study emphasizes the importance for *L. monocytogenes* virulence of compartmentalizing the activity of PC-PLC, a membrane-acting factor that contributes to lysis of double-membrane vacuoles formed upon bacterial cell-to-cell spread. Constitutive secretion of active PC-PLC during intracellular infection causes host membrane damage in a cell-tocell spread-dependent manner and results in virulence attenuation in the mouse. Future studies will aim at elucidating the mechanism contributing to  $plcB\Delta$ pro mutant attenuation in vivo.

### **ACKNOWLEDGMENTS**

We thank D. A. Portnoy for providing strain DP-L3903, which was used in the in vivo experiments. We are also grateful to Heather O'Neil and Avni Shah for their assistance on the competitive index and bile salts resistance assays, respectively.

This work was supported by U.S. Public Health Service grant AI52154 to H.M. from NIAID.

#### **REFERENCES**

- 1. **Auerbuch, V., L. L. Lenz, and D. A. Portnoy.** 2001. Development of a competitive index assay to evaluate the virulence of *Listeria monocytogenes actA* mutants during primary and secondary infection of mice. Infect. Immun. **69:**5953–5957.
- 2. **Beauregard, K. E., K.-D. Lee, R. J. Collier, and J. A. Swanson.** 1997. pHdependent perforation of macrophage phagosomes by listeriolysin O from *Listeria monocytogenes*. J. Exp. Med. **186:**1159–1163.
- 3. **Bishop, D. K., and D. J. Hinrichs.** 1987. Adoptive transfer of immunity to *Listeria monocytogenes*: the influence of *in vitro* stimulation on lymphocyte subset requirements. J. Immunol. **139:**2005–2009.
- 4. **Camilli, A., L. G. Tilney, and D. A. Portnoy.** 1993. Dual roles of *plcA* in *Listeria monocytogenes* pathogenesis. Mol. Microbiol. **8:**143–157.
- 5. **Conlan, J. W., and R. J. North.** 1991. Neutrophil-mediated dissolution of infected host cells as a defense strategy against a facultative intracellular bacterium. J. Exp. Med. **174:**741–744.
- 6. **Cossart, P., M. F. Vicente, J. Mengaud, F. Baquero, J. C. Perez-Diaz, and P. Berche.** 1989. Listeriolysin O is essential for virulence of *Listeria monocytogenes*: direct evidence obtained by gene complementation. Infect. Immun. **57:**3629–3636.
- 7. **Decatur, A. L., and D. A. Portnoy.** 2000. A PEST-like sequence in listeriolysin O essential for *Listeria monocytogenes* pathogenicity. Science **290:**992– 995.
- 8. **Glomski, I. J., A. L. Decatur, and D. A. Portnoy.** 2003. *Listeria monocytogenes* mutants that fail to compartmentalize listeriolysin O activity are cytotoxic,

avirulent, and unable to evade host extracellular defenses. Infect. Immun. **71:**6754–6765.

- 9. **Gregory, S. H., A. J. Sagnimeni, and E. J. Wing.** 1996. Bacteria in the bloodstream are trapped in the liver and killed by immigrating neutrophils. J. Immunol. **157:**2514–2520.
- 10. **Grundling, A., M. D. Gonzalez, and D. E. Higgins.** 2003. Requirement of the *Listeria monocytogenes* broad-range phospholipase PC-PLC during infection of human epithelial cells. J. Bacteriol. **185:**6295–6307.
- 11. **Jones, S., and D. A. Portnoy.** 1994. Characterization of *Listeria monocytogenes* pathogenesis in a strain expressing perfringolysin O in place of listeriolysin O. Infect. Immun. **62:**5608–5613.
- 12. **Marquis, H., V. Doshi, and D. A. Portnoy.** 1995. The broad-range phospholipase C and a metalloprotease mediate listeriolysin O-independent escape of *Listeria monocytogenes* from a primary vacuole in human epithelial cells. Infect. Immun. **63:**4531–4534.
- 13. **Marquis, H., H. Goldfine, and D. A. Portnoy.** 1997. Proteolytic pathways of activation and degradation of a bacterial phospholipase C during intracellular infection by *Listeria monocytogenes*. J. Cell Biol. **137:**1381–1392.
- 14. **Marquis, H., and E. J. Hager.** 2000. pH-regulated activation and release of a bacteria-associated phospholipase C during intracellular infection by *Listeria monocytogenes*. Mol. Microbiol. **35:**289–298.
- 15. **Mounier, J., A. Ryter, M. Coquis-Rondon, and P. J. Sansonetti.** 1990. Intracellular and cell-to-cell spread of *Listeria monocytogenes* involves interaction with F-actin in the enterocytelike cell line Caco-2. Infect. Immun. **58:**1048–1058.
- 16. **Neumann, K., E. Eppler, L. Filgueira, P. Groscurth, E. Gasal, A. Schaffner, G. Schoedon, and M. Schneemann.** 2003. *Listeria* species escape from the phagosomes of interleukin-4-deactivated human macrophages independent of listeriolysin. Immunol. Cell Biol. **81:**431–439.
- 17. Niebuhr, K., T. Chakraborty, P. Köllner, and J. Wehland. 1993. Production of monoclonal antibodies to the phosphatidylcholine-specific phospholipase C of *Listeria monocytogenes*, a virulence factor for this species. Med. Microbiol. Lett. **2:**9–16.
- 18. **Portnoy, D. A., P. S. Jacks, and D. J. Hinrichs.** 1988. Role of hemolysin for the intracellular growth of *Listeria monocytogenes*. J. Exp. Med. **167:**1459– 1471.
- 19. **Poyart, C., E. Abachin, I. Razafimanantsoa, and P. Berche.** 1993. The zinc metalloprotease of *Listeria monocytogenes* is required for maturation of phosphatidylcholine phospholipase C: direct evidence obtained by gene complementation. Infect. Immun. **61:**1576–1580.
- 20. **Raveneau, J., C. Geoffroy, J.-L. Beretti, J.-L. Gaillard, J. E. Alouf, and P. Berche.** 1992. Reduced virulence of a *Listeria monocytogenes* phospholipasedeficient mutant obtained by transposon insertion into the zinc metalloprotease gene. Infect. Immun. **60:**916–921.
- 21. **Robbins, J. R., A. I. Barth, H. Marquis, E. L. de Hostos, W. J. Nelson, and J. A. Theriot.** 1999. *Listeria monocytogenes* exploits normal host cell processes to spread from cell to cell. J. Cell Biol. **146:**1333–1349.
- 22. **Schnupf, P., D. A. Portnoy, and A. L. Decatur.** 2006. Phosphorylation, ubiquitination and degradation of listeriolysin O in mammalian cells: role of the PEST-like sequence. Cell. Microbiol. **8:**353–364.
- 23. **Smith, G. A., H. Marquis, S. Jones, N. C. Johnston, D. A. Portnoy, and H. Goldfine.** 1995. The two distinct phospholipases C of *Listeria monocytogenes* have overlapping roles in escape from a vacuole and cell-to-cell spread. Infect. Immun. **63:**4231–4237.
- 24. **Snyder, A., and H. Marquis.** 2003. Restricted translocation across the cell wall regulates secretion of the broad-range phospholipase C of *Listeria monocytogenes*. J. Bacteriol. **185:**5953–5958.
- 25. **Sun, A. N., A. Camilli, and D. A. Portnoy.** 1990. Isolation of *Listeria monocytogenes* small-plaque mutants defective for intracellular growth and cellto-cell spread. Infect. Immun. **58:**3770–3778.
- 26. **Tilney, L. G., and D. A. Portnoy.** 1989. Actin filaments and the growth, movement, and spread of the intracellular bacterial parasite, Listeria monocytogenes. J. Cell Biol. **109:**1597–1608.
- 27. **Vazquez-Boland, J.-A., C. Kocks, S. Dramsi, H. Ohayon, C. Geoffroy, J. Mengaud, and P. Cossart.** 1992. Nucleotide sequence of the lecithinase operon of *Listeria monocytogenes* and possible role of lecithinase in cell-tocell spread. Infect. Immun. **60:**219–230.
- 28. **Yeung, P. S., N. Zagorski, and H. Marquis.** 2005. The metalloprotease of *Listeria monocytogenes* controls cell wall translocation of the broad-range phospholipase C. J. Bacteriol. **187:**2601–2608.